Literature DB >> 9310494

Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression.

M M Morente1, M A Piris, V Abraira, A Acevedo, B Aguilera, C Bellas, M Fraga, R Garcia-Del-Moral, F Gomez-Marcos, J Menarguez, H Oliva, M Sanchez-Beato, C Montalban.   

Abstract

Previous studies have shown that in non-Hodgkin's lymphomas and others neoplasms, tumoral progression, treatment response, and outcome are related to the expression of different oncogenic and tumor suppressor proteins. This study aimed to determine the prognostic significance of the expression of p53, bcl2, retinoblastoma protein (Rb), Ki67, CD15, and latent membrane protein 1-Epstein-Barr Virus (LMP1-EBV) proteins in Hodgkin's disease. A retrospective study was performed on 140 patients collected at the 11 participating centers belonging to the Spanish Collaborative Group for the Study of Hodgkin's Disease. A highly sensitive immunohistochemical method with previous microwave-induced antigen retrieval technique was used for the demonstration of the above-mentioned proteins. A Cox's multivariate analysis was performed to evaluate the impact of the variables in the overall survival, together with a logistic regression model for the achievement of complete remission. Univariate statistical analysis confirmed the prognostic significance of the alredy known clinical parameters: stage, age over 60 years, and B symptoms. High proliferation index (Ki67) and loss of Rb expression were also found to be adverse prognostic factors influencing respectively lower overall survival and failure to achieve complete remission. Multivariate analysis confirmed the independent significance of these two parameters and additionally identifies LMP1-EBV expression as a favorable prognostic marker, in relation with overall survival. Histopathological type, p53, bcl2, and CD15 expression lack significant influence on the outcome of this series. The progression of the disease or the response to treatment in HD patients is the consequence of the interrelationship of different factors, among which LMP1 expression, loss of Rb, and high growth fraction seems to play a more relevant role.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310494

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Hodgkin's disease and the Epstein-Barr virus.

Authors:  K J Flavell; P G Murray
Journal:  Mol Pathol       Date:  2000-10

2.  The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Vesna M Cemerikic Martinovic; Tamara K Kravic; Vladimir Z Bumbasirevic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases.

Authors:  M Engel; M F Essop; P Close; P Hartley; G Pallesen; C Sinclair-Smith
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

4.  CD30 expression and proliferative fraction in nontransformed mycosis fungoides.

Authors:  James T Edinger; Beth Z Clark; Brian E Pucevich; Larisa J Geskin; Steven H Swerdlow
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

5.  Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma.

Authors:  Antônio H J F M Campos; Vera L Aldred; Karina C B Ribeiro; José Vassallo; Fernando A Soares
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.396

6.  Epstein-Barr virus expression in Hodgkin's lymphoma in Kuwait.

Authors:  R R Makar; T Saji; T A Junaid
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

Review 7.  Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

Authors:  Luis de la Cruz-Merino; Marylène Lejeune; Esteban Nogales Fernández; Fernando Henao Carrasco; Ana Grueso López; Ana Illescas Vacas; Mariano Provencio Pulla; Cristina Callau; Tomás Álvaro
Journal:  Clin Dev Immunol       Date:  2012-08-15

Review 8.  Hodgkin's disease: prognostic factors and short-course regimens.

Authors:  N L Bartlett; S M Arackal
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

9.  Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases.

Authors:  Danielle Canioni; Bénédicte Deau-Fischer; Pierre Taupin; Vincent Ribrag; Richard Delarue; Jacques Bosq; Marie-Thérèse Rubio; Damien Roux; Viorel Vasiliu; Bruno Varet; Nicole Brousse; Olivier Hermine
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

10.  Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.

Authors:  Yuan Mao; Mei Ping Lu; Hong Lin; Da Wei Zhang; Ying Liu; Qing Dong Li; Zhi Gang Lv; Jia Ren Xu; Ren Jie Chen; Jin Zhu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.